JP3642945B2 - Skin pretreatment agent - Google Patents

Skin pretreatment agent Download PDF

Info

Publication number
JP3642945B2
JP3642945B2 JP07218498A JP7218498A JP3642945B2 JP 3642945 B2 JP3642945 B2 JP 3642945B2 JP 07218498 A JP07218498 A JP 07218498A JP 7218498 A JP7218498 A JP 7218498A JP 3642945 B2 JP3642945 B2 JP 3642945B2
Authority
JP
Japan
Prior art keywords
skin
pretreatment agent
skin pretreatment
lotion
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP07218498A
Other languages
Japanese (ja)
Other versions
JPH11269033A (en
Inventor
基 早瀬
美由紀 齋藤
Original Assignee
株式会社カネボウ化粧品
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社カネボウ化粧品 filed Critical 株式会社カネボウ化粧品
Priority to JP07218498A priority Critical patent/JP3642945B2/en
Publication of JPH11269033A publication Critical patent/JPH11269033A/en
Application granted granted Critical
Publication of JP3642945B2 publication Critical patent/JP3642945B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)

Description

【0001】
【発明の属する技術分野】
本発明は皮膚プレトリートメント剤に関する。更に詳しくは、化粧水の使用の前に皮膚に塗布することにより、化粧水が含有する低分子水溶性有効成分の経皮吸収性を高め、化粧水の効果を高める皮膚プレトリートメント剤に関する。
【0002】
【従来の技術】
皮膚に対し有効性を示す物質には、荒れ肌改善物質であるジイソプロピルアミンジクロロアセテートやコラーゲン産生促進物質であるアスコルビン酸誘導体などの水溶性物質が多い。そこで水溶性物質を含有した化粧水剤形の皮膚外用剤が多く提案されている。一方、一般に水溶性物質は油溶性物質に比較して経皮吸収性が低い。そこで、水溶性物質の経皮吸収性を高める物質の探索が行われている。これまでにもセスキテルペン類やイソステアリン酸などの油剤に水溶性物質の経皮吸収促進効果を見出した(特開平6−135821号公報など)。これら経皮吸収促進物質は吸収促進させたい水溶性物質と同一製剤中に共存することによりその効果を示す。しかしながら、上記油剤を共存させた場合、製剤は乳化物となり、安定性や感触など剤形上の制約を受ける。よって、官能的に好まれ、熱力学的に安定な化粧水剤中に配合された水溶性成分を効率よく皮膚から吸収させることは困難であった。
【0003】
【発明が解決しようとする課題】
本発明は、このような実情に鑑みなされたものであって、化粧水が含有する低分子水溶性有効成分の経皮吸収性を高める皮膚プレトリートメント剤を提供することを目的とするものである。
【0004】
【課題を解決するための手段】
上記の目的を達成するために、本発明の皮膚プレトリートメント剤は、経皮吸収促進効果を有する極性油剤を配合することを特徴とするものである。
【0005】
【発明の実施の形態】
以下、本発明の実施の形態を述べる。一般に経皮吸収促進物質は吸収促進させたい水溶性物質と同一製剤中に共存する。本発明の皮膚プレトリートメント剤は化粧水の使用の前に皮膚に塗布することにより、化粧水が含有する低分子水溶性有効成分の経皮吸収性を高め、有効成分の効果を高める。
【0006】
本発明の皮膚プレトリートメント剤に用いられる極性油剤としては、例えばイソステアリン酸、オレイン酸、イソ型長鎖脂肪酸、アンテイソ型長鎖脂肪酸などの高級脂肪酸、オリーブ油、マカデミアナッツ油などの植物油、リモネン、水素添加ビサボロール等のテルペン類、2−エチルヘキサン酸グリセリルなどのトリグリセリド、ミリスチン酸イソプロピル等のエステル油が挙げられる。極性油剤の配合量は、プレトリートメント剤(組成物)の総量を基準として各々0.01〜10重量%(以下、wt%と略記する)が望ましい。これらの配合量の上限を超えても、その越えた配合量に見合った効果は期待できず、また下限未満の配合量では本発明の目的を達成することができない場合がある。
【0007】
本発明の皮膚プレトリートメント剤は医薬品、化粧品等に適用でき、剤形としては例えば、乳液類、クリーム類、パック類、マッサージ料類等に適用することができる。本発明の皮膚プレトリートメント剤のpHは6〜8が望ましい。6未満であると塩基性物質の吸収が悪く、8を超えると酸性物質の吸収が悪くなる場合がある。
【0008】
尚、本発明の皮膚プレトリートメント剤には上記の他にタール系色素、酸化鉄などの着色顔料、パラベン、フェノキシエタノールなどの防腐剤、ジメチルポリシロキサン、メチルフェニルポリシロキサン等のシリコン油、パラフィン、ワセリン等の炭化水素類、ミツロウ、モクロウ、カルナバロウ等のロウ類、エタノール等の低級アルコール類、セタノール、ベヘニルアルコール、ステアリルアルコール等の高級アルコール類、コレステロール、フィトステロール、分岐脂肪酸コレステロールエステル等のステロール類、硬化油等の加工油類、セチル硫酸ナトリウム、N−ステアロイル−L−グルタミン酸塩、グリチルリチン酸塩などの陰イオン界面活性剤、ポリオキシエチレンアルキルエーテル、ポリオキシエチレン脂肪酸エステル、ポリオキシエチレン多価アルコール脂肪酸エステル、ポリオキシエチレン硬化ヒマシ油、多価アルコール脂肪酸エステル、ポリグリセリン脂肪酸エステル、変性シリコン、蔗糖エステルなどの非イオン界面活性剤、テトラアルキルアンモニウム塩などの陽イオン界面活性剤、ベタイン型、スルホベタイン型、スルホアミノ酸型などの両性界面活性剤、レシチン、リゾフォスファチジルコリン、セラミド、セレブロシドなどの天然系界面活性剤、酸化チタン、酸化亜鉛などの顔料、ジブチルヒドロキシトルエンなどの抗酸化剤、塩化ナトリウム、塩化マグネシウム、硫酸ナトリウム、硝酸カリウム等の無機塩類、クエン酸ナトリウム、酢酸カリウム、琥珀酸ナトリウム、アスパラギン酸ナトリウム等の有機酸塩類、塩酸エタノールアミン、硝酸アンモニウム、塩酸アルギニン等の塩類、エデト酸等のキレート剤、キサンタンガム、カルボキシビニルポリマー、カラギーナンアルキル変性カルボキシビニルポリマー等の増粘剤、水酸化カリウム、ジイソプロパノールアミン、トリエタノールアミン等の中和剤、ヒアルロン酸、コラーゲン等の生体高分子、乳酸菌、酵母などの培養生成物、カミツレ、アロエ、モモ、カロット、スギナ、クワ、桃の葉、セージ、ビワ葉、キュウカンバー、セイヨウキズタ、ハイビスカス、ウコン、ローズマリー、甘草等の植物エキス、セリン、スレオニン等のアミノ酸、ヒドロキシメトキシベンゾフェノンスルフォン酸塩等の紫外線吸収剤、ジプロピレングリコール、1,3ブチレングリコール、グリセリン、プロピレングリコール、ソルビトール、マルビトール、ジグリセリンなどの多価アルコール等が挙げられるがこれに限定されるものではない。
【0009】
【実施例】
以下、実施例及び比較例に基づいて本発明を詳細に説明する。尚、実施例に記載の経皮吸収量測定試験、荒れ肌改善試験は下記の通りである。
【0010】
(経皮吸収量測定試験)
フランツ型垂直セルにヘアレスラットの腹部皮膚を装着し、表1に示す実施例1の本発明の皮膚プレトリートメント剤(pH6.8)を塗布した後、14Cでラベルしたジイソプロピルアミン200000dpmを含む化粧水を1ml乗せた後、24時間後の透過量を液体シンチレーションカウンターにて測定した。対照(比較例1)として本発明のプレトリートメント剤を塗布せずに14Cでラベルしたジイソプロピルアミンを含む化粧水を1ml乗せた後、同様にして測定した。
【0011】
(荒れ肌改善試験)
成人女性30名の顔面に表1に示す実施例1の本発明の皮膚プレトリートメント剤(pH6.8)を塗布した後、化粧水(ジイソプロピルアミンジクロロアセテート0.5%、エタノール5%、グリセリン3%、ジプロピレングリコール10%、精製水残量)を塗布した(一日2回)。対照(比較例1)として、本発明のプレトリートメント剤を塗布せずに上記と同様のジイソプロピルアミンジクロロアセテート0.5%配合化粧水のみを塗布した(一日2回)。荒れ肌改善の効果は、3週間後の荒れ肌の改善の見られた人数で示した。
(1)組成
【0012】
【表1】

Figure 0003642945
【0013】
(2)特性
各試験例の前記諸特性を試験した結果を表2に示す。この表に示す如く、本発明の皮膚プレトリートメント剤(実施例1)は皮膚プレトリートメント剤を用いない比較例1に比べ、優れた経皮吸収促進性、荒れ肌改善効果を示した。
【0014】
【表2】
Figure 0003642945
【0015】
【発明の効果】
以上記載のごとく、本発明が、化粧水が含有する低分子水溶性有効成分の経皮吸収性を高める皮膚プレトリートメント剤を提供することは明らかである。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a skin pretreatment agent. More specifically, by applying to the skin prior to use lotion, enhance transdermal absorption of the low molecular water soluble active ingredient lotion contains, related skin pretreatment agent to enhance the effect of the lotion.
[0002]
[Prior art]
Substances that are effective against the skin include many water-soluble substances such as diisopropylamine dichloroacetate, which is a rough skin improving substance, and ascorbic acid derivatives, which are collagen production promoting substances. Thus, many skin external preparations containing a water-soluble substance have been proposed. On the other hand, water-soluble substances are generally less transdermally absorbable than oil-soluble substances. Therefore, a search for a substance that enhances the transdermal absorbability of a water-soluble substance has been conducted. So far, an oil agent such as sesquiterpenes and isostearic acid has been found to promote transdermal absorption of a water-soluble substance (Japanese Patent Laid-Open No. 6-135821). These percutaneous absorption-enhancing substances exhibit their effects when they coexist in the same preparation with a water-soluble substance to be absorbed. However, when the above oil agent coexists, the preparation becomes an emulsion and is restricted in dosage form such as stability and feel. Therefore, it has been difficult to efficiently absorb the water-soluble component blended in the cosmetically preferred and thermodynamically stable lotion from the skin.
[0003]
[Problems to be solved by the invention]
The present invention was made in view of such circumstances, it is an object to provide a skin pretreatment agent to enhance the percutaneous absorbability of the low-molecular water-soluble active ingredient lotion contains .
[0004]
[Means for Solving the Problems]
In order to achieve the above object, the skin pretreatment agent of the present invention is characterized by blending a polar oil agent having a transdermal absorption promoting effect.
[0005]
DETAILED DESCRIPTION OF THE INVENTION
Embodiments of the present invention will be described below. In general, a transdermal absorption enhancer coexists in the same preparation with a water-soluble substance to be absorbed. When the skin pretreatment agent of the present invention is applied to the skin before the use of the skin lotion, the percutaneous absorbability of the low molecular weight water-soluble active ingredient contained in the skin lotion is enhanced and the effect of the active ingredient is enhanced.
[0006]
Examples of the polar oil used in the skin pretreatment agent of the present invention include higher fatty acids such as isostearic acid, oleic acid, iso-type long chain fatty acid, anteiso-type long chain fatty acid, vegetable oils such as olive oil and macadamia nut oil, limonene, and hydrogenated Examples include terpenes such as bisabolol, triglycerides such as glyceryl 2-ethylhexanoate, and ester oils such as isopropyl myristate. The blending amount of the polar oil agent is preferably 0.01 to 10% by weight (hereinafter abbreviated as wt%) based on the total amount of the pretreatment agent (composition). Even if the upper limit of these blending amounts is exceeded, an effect commensurate with the exceeding blending amount cannot be expected, and if the blending amount is less than the lower limit, the object of the present invention may not be achieved.
[0007]
The skin pretreatment agent of the present invention can be applied to pharmaceuticals, cosmetics and the like, and the dosage form can be applied to, for example, emulsions, creams, packs, massage materials and the like. The pH of the skin pretreatment agent of the present invention is preferably 6-8. If it is less than 6, absorption of the basic substance may be poor, and if it exceeds 8, absorption of the acidic substance may be deteriorated.
[0008]
In addition to the above, the skin pretreatment agent of the present invention includes tar pigments, colored pigments such as iron oxide, preservatives such as parabens and phenoxyethanol, silicone oils such as dimethylpolysiloxane and methylphenylpolysiloxane, paraffin, and petroleum jelly. Hydrocarbons such as beeswax, beeswax, carnauba wax and the like, lower alcohols such as ethanol, higher alcohols such as cetanol, behenyl alcohol and stearyl alcohol, sterols such as cholesterol, phytosterol and branched fatty acid cholesterol ester, and hardened oil Processing oils such as sodium cetyl sulfate, N-stearoyl-L-glutamate, glycyrrhizinate and the like, polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, poly Nonionic surfactants such as xylethylene polyhydric alcohol fatty acid ester, polyoxyethylene hydrogenated castor oil, polyhydric alcohol fatty acid ester, polyglycerin fatty acid ester, modified silicon, sucrose ester, cationic surfactant such as tetraalkylammonium salt, Amphoteric surfactants such as betaine type, sulfobetaine type, sulfoamino acid type, natural surfactants such as lecithin, lysophosphatidylcholine, ceramide, cerebroside, pigments such as titanium oxide and zinc oxide, dibutylhydroxytoluene, etc. Antioxidants, inorganic salts such as sodium chloride, magnesium chloride, sodium sulfate, potassium nitrate, organic acid salts such as sodium citrate, potassium acetate, sodium oxalate, sodium aspartate, ethanolamine hydrochloride, ammonium nitrate Salts such as nium, arginine hydrochloride, chelating agents such as edetic acid, thickeners such as xanthan gum, carboxyvinyl polymer, carrageenan alkyl-modified carboxyvinyl polymer, neutralizing agents such as potassium hydroxide, diisopropanolamine, triethanolamine, Biopolymers such as hyaluronic acid, collagen, culture products such as lactic acid bacteria, yeast, chamomile, aloe, peach, carrot, horsetail, mulberry, peach leaf, sage, loquat leaf, cucumber, lizard, hibiscus, turmeric, Plant extracts such as rosemary and licorice, amino acids such as serine and threonine, UV absorbers such as hydroxymethoxybenzophenone sulfonate, dipropylene glycol, 1,3 butylene glycol, glycerin, propylene glycol, sorbitol, malbito And polyhydric alcohols such as diglycerin and the like, but are not limited thereto.
[0009]
【Example】
Hereinafter, the present invention will be described in detail based on examples and comparative examples. In addition, the percutaneous absorption measurement test and the rough skin improvement test described in the Examples are as follows.
[0010]
(Transdermal absorption measurement test)
A hairless rat abdomen skin was attached to a Franz-type vertical cell, and after applying the skin pretreatment agent (pH 6.8) of the present invention of Example 1 shown in Table 1, a skin lotion containing 200,000 dpm of diisopropylamine labeled with 14C. After 1 ml was placed, the permeation amount after 24 hours was measured with a liquid scintillation counter. As a control (Comparative Example 1), 1 ml of a lotion containing diisopropylamine labeled with 14C was applied without applying the pretreatment agent of the present invention, and the measurement was performed in the same manner.
[0011]
(Rough skin improvement test)
After applying the skin pretreatment agent (pH 6.8) of the present invention of Example 1 shown in Table 1 on the face of 30 adult women, lotion (diisopropylamine dichloroacetate 0.5%, ethanol 5%, glycerin 3) %, Dipropylene glycol 10%, remaining amount of purified water) were applied (twice a day). As a control (Comparative Example 1), only a lotion containing 0.5% diisopropylamine dichloroacetate similar to the above was applied without applying the pretreatment agent of the present invention (twice a day). The effect of improving rough skin was shown by the number of people who showed improvement of rough skin after 3 weeks.
(1) Composition [0012]
[Table 1]
Figure 0003642945
[0013]
(2) Characteristics Table 2 shows the results of testing the various characteristics of each test example. As shown in this table, the skin pretreatment agent (Example 1) of the present invention exhibited superior transdermal absorption promotion and rough skin improvement effect as compared with Comparative Example 1 in which no skin pretreatment agent was used.
[0014]
[Table 2]
Figure 0003642945
[0015]
【The invention's effect】
As described above, the present invention, it is clear that providing a skin pretreatment agent to enhance the percutaneous absorbability of the low-molecular water-soluble active ingredient lotion contains.

Claims (4)

イソステアリン酸、オレイン酸、リモネン、2−エチルヘキサン酸グリセリル、ミリスチン酸イソプロピルからなる群より選択される1種又は2種以上を配合することを特徴とする皮膚プレトリートメント剤を、化粧水の使用の前に皮膚に塗布することを特徴とする皮膚プレトリートメント剤の使用方法。  A skin pretreatment agent characterized by comprising one or more selected from the group consisting of isostearic acid, oleic acid, limonene, glyceryl 2-ethylhexanoate, and isopropyl myristate, A method of using a skin pretreatment agent, characterized by being applied to the skin before. イソステアリン酸を配合することを特徴とする皮膚プレトリートメント剤を、化粧水の使用の前に皮膚に塗布することを特徴とする皮膚プレトリートメント剤の使用方法。  A method for using a skin pretreatment agent, which comprises applying a skin pretreatment agent characterized by blending isostearic acid to the skin before using the skin lotion. 化粧水が、ジイソプロピルアミンジクロロアセテートを含有することを特徴とする請求項1又は2に記載の皮膚プレトリートメント剤の使用方法。  The method of using a skin pretreatment agent according to claim 1 or 2, wherein the skin lotion contains diisopropylamine dichloroacetate. 皮膚プレトリートメント剤が、化粧品又は医薬品であることを特徴とする請求項1〜3のいずれか1項に記載の皮膚プレトリートメント剤の使用方法。  The method for using a skin pretreatment agent according to any one of claims 1 to 3, wherein the skin pretreatment agent is a cosmetic or a pharmaceutical product.
JP07218498A 1998-03-20 1998-03-20 Skin pretreatment agent Expired - Fee Related JP3642945B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP07218498A JP3642945B2 (en) 1998-03-20 1998-03-20 Skin pretreatment agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP07218498A JP3642945B2 (en) 1998-03-20 1998-03-20 Skin pretreatment agent

Publications (2)

Publication Number Publication Date
JPH11269033A JPH11269033A (en) 1999-10-05
JP3642945B2 true JP3642945B2 (en) 2005-04-27

Family

ID=13481887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP07218498A Expired - Fee Related JP3642945B2 (en) 1998-03-20 1998-03-20 Skin pretreatment agent

Country Status (1)

Country Link
JP (1) JP3642945B2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078185A1 (en) * 2003-03-04 2004-09-16 Neochemir Inc. Method of transdermal and transmucosal absorption of carbon dioxide and cosmetic method and therapeutic method
CZ201110A3 (en) * 2008-07-10 2011-02-09 Unilever N.V. Method of lightening skin
JP5726489B2 (en) * 2010-11-26 2015-06-03 株式会社ノエビア Skin pretreatment agent
JP5973256B2 (en) * 2011-06-29 2016-08-23 株式会社コーセー Skin care method and cosmetics used therefor
JP6730241B2 (en) * 2017-10-04 2020-07-29 花王株式会社 Skin care methods

Also Published As

Publication number Publication date
JPH11269033A (en) 1999-10-05

Similar Documents

Publication Publication Date Title
KR100859677B1 (en) Pharmaceutical compositions for reducing the appearance of dark circles under the eyes
BR112020019875A2 (en) TOPICAL COMPOSITIONS FOR PAIN RELIEF
JPS63185912A (en) Cosmetic
JP2021042241A (en) Composition for external use
JP4518367B2 (en) Pore reducing agent
JP3642945B2 (en) Skin pretreatment agent
KR20150072797A (en) Composition comprising high concentration caffeines
JP2001233754A (en) Emulsion type skin care preparation
US9987322B1 (en) Treatment of pain in peripheral neuropathy using topical hamelia patens extract
JPH11139951A (en) Cosmetic
JP7313111B2 (en) Sebum secretion stimulator and composition for external use
JP3441387B2 (en) Moisturizer, skin cosmetics and bath additives
JP6654369B2 (en) Elastase inhibitor
JPH07215838A (en) Skin external agent
JP3556479B2 (en) Skin pre-treatment agent
JPH05301812A (en) Skin external preparation
JPH09176030A (en) Medicine for stimulating secretion of sebum
JPH1160462A (en) Skin cosmetic
JP2001278768A (en) Skin care preparation
JP4647733B2 (en) Transdermal absorption-enhancing topical agent
JP3400313B2 (en) Percutaneous absorption promoting skin external preparation
JP7253328B2 (en) External pharmaceutical composition
JP2007008911A (en) Cosmetic
JP2001206834A (en) Skin preparation for external use
JPH1160433A (en) Skin cosmetic

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040805

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20041109

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041125

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20041125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20050125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20050126

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080204

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090204

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090204

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100204

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100204

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110204

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120204

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120204

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130204

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140204

Year of fee payment: 9

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees